Jun 03, 2021 / 05:30PM GMT
Michael Jonathan Yee - Jefferies LLC, Research Division - Equity Analyst
Well, hello, everyone, and good afternoon, and thank you for joining us on another great session here at the Jefferies at Global Health Care Conference. We have a great team here from Amgen on with us. Certainly a lot to talk about. Members of the team here include Murdo Gordon, Executive Vice President of Global Commercial Operations. We have the pleasure of having Susan Sweeney on, who's SVP of Global Marketing Access and Capabilities and probably a good tag team to talk about a lot of drugs that are launching around the world. And of course, we all know Vice President of Investor Relations, Arvind Sood.
To that extent, I'd love that, Arvind, maybe just kick off perhaps with some high-level comments about the state of affairs, and that will be a good icebreaker to perhaps lead off into some other additional topics. So Arvind, tell us about what's going on at Amgen.
Arvind Sood - Amgen Inc. - VP of IR
Thank you very much, Mike, and thanks for having us. Really appreciate this
Amgen Inc at Jefferies Healthcare Conference (Virtual) Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot